Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

From the Women's Health Initiative to the combination of estrogen and selective estrogen receptor modulators to avoid progestin addition.

Valera MC, Gourdy P, Trémollières F, Arnal JF.

Maturitas. 2015 Nov;82(3):274-7. doi: 10.1016/j.maturitas.2015.07.012. Review.

PMID:
26261036
2.

Alopecia with endocrine therapies in patients with cancer.

Saggar V, Wu S, Dickler MN, Lacouture ME.

Oncologist. 2013;18(10):1126-34. doi: 10.1634/theoncologist.2013-0193.

3.

Update on raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications.

Gizzo S, Saccardi C, Patrelli TS, Berretta R, Capobianco G, Di Gangi S, Vacilotto A, Bertocco A, Noventa M, Ancona E, D'Antona D, Nardelli GB.

Obstet Gynecol Surv. 2013 Jun;68(6):467-81. doi: 10.1097/OGX.0b013e31828baef9. Review.

PMID:
23942473
4.

Exemestane: one part of the chemopreventive spectrum for ER-positive breast cancer.

Dunn BK, Cazzaniga M, DeCensi A.

Breast. 2013 Jun;22(3):225-37. doi: 10.1016/j.breast.2013.02.015. Review.

PMID:
23535509
5.

The use of raloxifene in osteoporosis treatment.

D'Amelio P, Isaia GC.

Expert Opin Pharmacother. 2013 May;14(7):949-56. doi: 10.1517/14656566.2013.782002. Review.

PMID:
23521229
6.

Breast cancer chemoprevention.

Gabriel EM, Jatoi I.

Expert Rev Anticancer Ther. 2012 Feb;12(2):223-8. doi: 10.1586/era.11.206. Review.

PMID:
22316370
7.

The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.

Jordan VC, Obiorah I, Fan P, Kim HR, Ariazi E, Cunliffe H, Brauch H.

Breast. 2011 Oct;20 Suppl 3:S1-11. doi: 10.1016/S0960-9776(11)70287-9.

8.

Exemestane for breast-cancer prevention in postmenopausal women.

Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H; NCIC CTG MAP.3 Study Investigators..

N Engl J Med. 2011 Jun 23;364(25):2381-91. doi: 10.1056/NEJMoa1103507. Erratum in: N Engl J Med. 2011 Oct 6;365(14):1361.

9.

Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.

Ko SS, Jordan VC.

Expert Opin Pharmacother. 2011 Mar;12(4):657-74. doi: 10.1517/14656566.2011.557360. Review. Retraction in: Expert Opin Pharmacother. 2012 May;13(7):1081.

10.

Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.

Vogel VG.

Curr Drug Targets. 2011 Dec;12(13):1874-87. Review.

PMID:
21158712
11.

Breast cancer chemoprevention - a vision not yet realized.

Blaha P, Dubsky P, Fitzal F, Bachleitner-Hofmann T, Jakesz R, Gnant M, Steger G.

Eur J Cancer Care (Engl). 2009 Sep;18(5):438-46. doi: 10.1111/j.1365-2354.2008.00951.x. Review.

PMID:
19686352
12.

Raloxifene: a review of its use in the prevention of invasive breast cancer.

Moen MD, Keating GM.

Drugs. 2008;68(14):2059-83. Review.

PMID:
18778124
13.

Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.

Ganz PA, Land SR.

Menopause. 2008 Jul-Aug;15(4 Suppl):797-803. doi: 10.1097/gme.0b013e31817be9af. Review.

PMID:
18596601
14.

Subcutaneous mastectomy and immediate reconstruction for prevention of breast cancer for high-risk patients.

Ashikari RH, Ashikari AY, Kelemen PR, Salzberg CA.

Breast Cancer. 2008;15(3):185-91. doi: 10.1007/s12282-008-0059-7.

PMID:
18575951
15.

Breast cancer risk management.

Reeder JG, Vogel VG.

Clin Breast Cancer. 2007 Dec;7(11):833-40. doi: 10.3816/CBC.2007.n.047. Review.

PMID:
18269772
16.

Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches.

Land SR, Ritter MW, Costantino JP, Julian TB, Cronin WM, Haile SR, Wolmark N, Ganz PA.

J Clin Oncol. 2007 Nov 10;25(32):5113-20. Review.

PMID:
17991930
17.

Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia.

Meadows ES, Klein R, Rousculp MD, Smolen L, Ohsfeldt RL, Johnston JA.

BMC Womens Health. 2007 Apr 17;7:6.

18.

Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer.

Eng-Wong J, Reynolds JC, Venzon D, Liewehr D, Gantz S, Danforth D, Liu ET, Chow C, Zujewski J.

J Clin Endocrinol Metab. 2006 Oct;91(10):3941-6.

PMID:
16868059
19.

Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, Pajon ER, Wade JL 3rd, Dakhil S, Lockhart JB Jr, Wolmark N, Ganz PA.

JAMA. 2006 Jun 21;295(23):2742-51. Erratum in: JAMA. 2007 Sep 5;298(9):973.

PMID:
16754728
20.

Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study.

Kanis JA, Borgström F, Johnell O, Oden A, Sykes D, Jönsson B.

Osteoporos Int. 2005 Jan;16(1):15-25.

PMID:
15672210
Items per page

Supplemental Content

Loading ...
Support Center